Psilocybin Drug By Psilera Could Treat Frontotemporal Dementia Without Psychoactive Effects
Psilera, a Tampa-based biotech company, has taken a significant step in advancing treatments for dementia with its psilocybin-based drug, PSIL-006. Unlike traditional psychedelics, this pharmaceutical version of psilocybin is designed to avoid inducing the hallucinogenic effects commonly associated with “magic” mushrooms, paving the way for more accessible therapies.
The company recently announced that PSIL-006 had successfully cleared a key safety milestone in preclinical studies, demonstrating a “strong” safety profile. This progress marks an important step toward future human trials and, potentially, FDA approval. If successful, the drug could address frontotemporal dementia (FTD), a condition that affects nearly 60 million Americans and currently lacks any FDA-approved treatments.
Read Also: ‘Psychedelics Are Here To Stay And They Belong To Everyone,’ Says Mycopreneur’s Dennis Walker
Advancing Dementia Treatment Without Psychedelic Effects
Psilera’s PSIL-006 was tested in models that mimic FTD, showing promising improvements in memory, sleep, and learning. However, further research and rigorous clinical trials, including human testing, will …